300685 艾德生物
已收盘 05-16 15:00:00
资讯
新帖
简况
艾德生物(300685.SZ)股东厦门屹祥拟减持不超3%股份
智通财经 · 05-06
艾德生物(300685.SZ)股东厦门屹祥拟减持不超3%股份
艾德生物：厦门屹祥拟减持不超3.00%公司股份
美港电讯 · 05-06
艾德生物：厦门屹祥拟减持不超3.00%公司股份
艾德生物(300685.SZ)发布2024年度业绩，归母净利润2.55亿元，同比下降2.53%
智通财经 · 04-21
艾德生物(300685.SZ)发布2024年度业绩，归母净利润2.55亿元，同比下降2.53%
艾德生物(300685.SZ)发布一季度业绩，归母净利润9047.18万元，同比增长40.92%
智通财经 · 04-21
艾德生物(300685.SZ)发布一季度业绩，归母净利润9047.18万元，同比增长40.92%
艾德生物(300685.SZ)完成回购 累计耗资1.01亿元回购1.35%股份
智通财经 · 02-25
艾德生物(300685.SZ)完成回购 累计耗资1.01亿元回购1.35%股份
【艾德生物：收到医疗器械变更注册文件】金融界2月20日消息，厦门艾德生物医药科技股份有限公司于近日收到国家药品监督管理局颁发的《医疗器械变更注册文件》，已完成“PD-L1抗体试剂（免疫组织化学法）”产品原注册证相关事项的变更。变更内容为预期用途增加相关表述。公司PD-L1抗体试剂已获批用于非小细胞肺癌、胃癌及胃食管交界处腺癌的伴随诊断。此次变更显著增强公司综合竞争力与市场拓展能力，产品实际销售情况取决于未来市场推广效果，尚无法预测对公司未来业绩的影响。
金融界 · 02-20
【艾德生物：收到医疗器械变更注册文件】金融界2月20日消息，厦门艾德生物医药科技股份有限公司于近日收到国家药品监督管理局颁发的《医疗器械变更注册文件》，已完成“PD-L1抗体试剂（免疫组织化学法）”产品原注册证相关事项的变更。变更内容为预期用途增加相关表述。公司PD-L1抗体试剂已获批用于非小细胞肺癌、胃癌及胃食管交界处腺癌的伴随诊断。此次变更显著增强公司综合竞争力与市场拓展能力，产品实际销售情况取决于未来市场推广效果，尚无法预测对公司未来业绩的影响。
艾德生物(300685.SZ)累计回购1.28%股份 耗资9509.46万元
智通财经 · 02-06
艾德生物(300685.SZ)累计回购1.28%股份 耗资9509.46万元
艾德生物(300685.SZ)获得两项医疗器械注册证
智通财经 · 01-13
艾德生物(300685.SZ)获得两项医疗器械注册证
一周复盘 | 艾德生物本周累计下跌1.67%，医疗器械板块下跌3.36%
金融界 · 2024-12-29
一周复盘 | 艾德生物本周累计下跌1.67%，医疗器械板块下跌3.36%
艾德生物(300685.SZ)获得一项医疗器械注册证
智通财经 · 2024-11-28
艾德生物(300685.SZ)获得一项医疗器械注册证
艾德生物(300685.SZ)累计回购1.17%股份 耗资8583.5万元
智通财经 · 2024-11-04
艾德生物(300685.SZ)累计回购1.17%股份 耗资8583.5万元
加载更多
公司概况
公司名称：
厦门艾德生物医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2017-08-02
主营业务：
厦门艾德生物医药科技股份有限公司的主营业务是肿瘤基因检测试剂、软件及配套仪器，并提供检测服务及药物临床研究服务。公司的主要产品是检测试剂、检测服务、药物临床研究服务。
发行价格：
13.86
{"stockData":{"symbol":"300685","market":"SZ","secType":"STK","nameCN":"艾德生物","latestPrice":20.2,"timestamp":1747379001000,"preClose":20.27,"halted":0,"volume":4144762,"delay":0,"changeRate":-0.0035,"floatShares":390000000,"shares":393000000,"eps":0.7153,"marketStatus":"已收盘","change":-0.07,"latestTime":"05-16 15:00:00","open":20.21,"high":20.33,"low":20.17,"amount":83843200,"amplitude":0.0079,"askPrice":20.22,"askSize":61,"bidPrice":20.2,"bidSize":470,"shortable":0,"etf":0,"ttmEps":0.7153,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747618200000},"marketStatusCode":5,"adr":0,"adjPreClose":20.27,"symbolType":"stock","openAndCloseTimeList":[[1747359000000,1747366200000],[1747371600000,1747378800000]],"highLimit":22.3,"lowLimit":18.24,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":393061969,"isCdr":false,"pbRate":4.15,"roa":"--","peRate":28.239899,"roe":"4.94%","epsLYR":0.64,"committee":0.662228,"marketValue":7940000000,"turnoverRate":0.0106,"status":1,"floatMarketCap":7870000000},"requestUrl":"/m/hq/s/300685","defaultTab":"news","newsList":[{"id":"2533658054","title":"艾德生物(300685.SZ)股东厦门屹祥拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2533658054","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533658054?lang=zh_cn&edition=full","pubTime":"2025-05-06 22:40","pubTimestamp":1746542423,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布公告，公司于近日收到股东厦门市屹祥投资合伙企业(有限合伙)(“厦门屹祥”)出具的《减持计划告知函》，拟减持数量不超过1179.18万股，即不超过公司总股本的3.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300685","LU2460026573.USD","BK0239","BK0042","IE0005HP3H50.USD"],"gpt_icon":0},{"id":"2533563487","title":"艾德生物：厦门屹祥拟减持不超3.00%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2533563487","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533563487?lang=zh_cn&edition=full","pubTime":"2025-05-06 21:39","pubTimestamp":1746538777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300685","LU2460026573.USD","BK0239","BK0042","IE0005HP3H50.USD"],"gpt_icon":0},{"id":"2529545873","title":"艾德生物(300685.SZ)发布2024年度业绩，归母净利润2.55亿元，同比下降2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529545873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529545873?lang=zh_cn&edition=full","pubTime":"2025-04-21 17:42","pubTimestamp":1745228573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布2024年年度报告，报告期内，公司实现营业收入11.09亿元，同比增长6.27%。实现归属于上市公司股东的净利润2.55亿元，同比下降2.53%。实现归属于上市公司股东的扣除非经常性损益的净利润2.33亿元，同比下降2.45%。基本每股收益为0.64元。拟向全体股东每 10 股派发现金红利3元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300685"],"gpt_icon":0},{"id":"2529325873","title":"艾德生物(300685.SZ)发布一季度业绩，归母净利润9047.18万元，同比增长40.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529325873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529325873?lang=zh_cn&edition=full","pubTime":"2025-04-21 17:37","pubTimestamp":1745228272,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布2025年一季度报告，第一季度，公司实现营业收入2.72亿元，同比增长16.63%。归属于上市公司股东的净利润9047.18万元，同比增长40.92%。归属于上市公司股东的扣除非经常性损益的净利润8722.35万元，同比增长53.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300685"],"gpt_icon":0},{"id":"2514528069","title":"艾德生物(300685.SZ)完成回购 累计耗资1.01亿元回购1.35%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2514528069","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514528069?lang=zh_cn&edition=full","pubTime":"2025-02-25 18:09","pubTimestamp":1740478144,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)公告，公司回购股份方案已实施完毕，截至2025年2月25日，公司以集中竞价交易方式累计回购公司股份537.48万股，占公司当前总股本的比例为1.35%，成交总金额为1.01亿元(不含交易费用)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK0239","IE0005HP3H50.USD","BK0042","300685"],"gpt_icon":0},{"id":"2512349084","title":"【艾德生物：收到医疗器械变更注册文件】金融界2月20日消息，厦门艾德生物医药科技股份有限公司于近日收到国家药品监督管理局颁发的《医疗器械变更注册文件》，已完成“PD-L1抗体试剂（免疫组织化学法）”产品原注册证相关事项的变更。变更内容为预期用途增加相关表述。公司PD-L1抗体试剂已获批用于非小细胞肺癌、胃癌及胃食管交界处腺癌的伴随诊断。此次变更显著增强公司综合竞争力与市场拓展能力，产品实际销售情况取决于未来市场推广效果，尚无法预测对公司未来业绩的影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512349084","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512349084?lang=zh_cn&edition=full","pubTime":"2025-02-20 15:56","pubTimestamp":1740038163,"startTime":"0","endTime":"0","summary":"金融界2月20日消息，厦门艾德生物医药科技股份有限公司于近日收到国家药品监督管理局颁发的《医疗器械变更注册文件》，已完成“PD-L1抗体试剂（免疫组织化学法）”产品原注册证相关事项的变更。变更内容为预期用途增加相关表述。公司PD-L1抗体试剂已获批用于非小细胞肺癌、胃癌及胃食管交界处腺癌的伴随诊断。此次变更显著增强公司综合竞争力与市场拓展能力，产品实际销售情况取决于未来市场推广效果，尚无法预测对公司未来业绩的影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20155648278395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09996","BK0042","LU2460026573.USD","300685","BK1583","LU1169590202.USD","159938","159883","BK1161","09939","LU1169589451.USD","PD","BK0239","BK1222","BK1515","BK1574","09997","IE0005HP3H50.USD","BK1100","BK4023"],"gpt_icon":0},{"id":"2509276982","title":"艾德生物(300685.SZ)累计回购1.28%股份 耗资9509.46万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509276982","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509276982?lang=zh_cn&edition=full","pubTime":"2025-02-06 20:16","pubTimestamp":1738844163,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)公告，公司截止2025年1月31日以集中竞价交易方式实施回购股份509.48万股，占公司目前总股本的1.28%，支付的总金额为9509.46万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300685","BK0239","BK0042","IE0005HP3H50.USD","LU2460026573.USD"],"gpt_icon":0},{"id":"2503761322","title":"艾德生物(300685.SZ)获得两项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2503761322","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503761322?lang=zh_cn&edition=full","pubTime":"2025-01-13 16:30","pubTimestamp":1736757016,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布公告，公司于近日获得由国家药品监督管理局颁发的两项《中华人民共和国医疗器械注册证》，产品名称分别为：HER-2抗体试剂(免疫组织化学)、雌激素受体抗体试剂(免疫组织化学法)。公司近期连续获得三款免疫组化诊断产品的批准：HER2(人表皮生长因子受体2)、ER(雌激素受体)和PR(孕激素受体)抗体试剂，用于指导乳腺癌患者的HER2靶向治疗和内分泌治疗。上述产品医疗器械注册证的取得，进一步丰富了公司产品布局，有利于增强公司综合竞争力，提高公司市场拓展能力，对公司未来的发展将产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0005HP3H50.USD","BK1574","BK0239","BK1222","LU2460026573.USD","BK0042","09997","300685","09996","159883","BK1100","BK1583"],"gpt_icon":0},{"id":"2495768183","title":"一周复盘 | 艾德生物本周累计下跌1.67%，医疗器械板块下跌3.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495768183","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495768183?lang=zh_cn&edition=full","pubTime":"2024-12-29 10:54","pubTimestamp":1735440871,"startTime":"0","endTime":"0","summary":"12月23日至12月27日本周创业板指下跌0.22%，医疗器械板块下跌3.36%。艾德生物本周累计下跌1.67%，周总成交额3.56亿元，截至本周收盘，艾德生物股价为23.55元。评级理由主要包括：1）艾德生物是国际领先的精准医疗分子诊断龙头企业；2）伴随诊断助力肿瘤精准医疗发展；3）公司在多个癌种已建立“研发+注册+销售”护城河。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/29105446919648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0042","BK0239","BK1100","300685","IE0005HP3H50.USD","BK1222","09997","159883","LU2460026573.USD","09996","BK1583","BK1574"],"gpt_icon":0},{"id":"2486585443","title":"艾德生物(300685.SZ)获得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2486585443","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486585443?lang=zh_cn&edition=full","pubTime":"2024-11-28 11:47","pubTimestamp":1732765640,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)发布公告，公司于近日获得由国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》，产品名称：孕激素受体抗体试剂(免疫组织化学法)，本试剂盒用于体外半定量检测经10%中性缓冲福尔马林固定石蜡包埋(FFPE)组织切片中孕激素受体。该产品医疗器械注册证的取得，进一步丰富了公司产品布局，有利于增强公司综合竞争力，提高公司市场拓展能力，对公司未来的发展将产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","BK1100","LU2460026573.USD","159883","300685","IE0005HP3H50.USD","09996","BK1222","BK1583","BK1574","BK0042","BK0239"],"gpt_icon":0},{"id":"2480379861","title":"艾德生物(300685.SZ)累计回购1.17%股份 耗资8583.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480379861","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480379861?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:00","pubTimestamp":1730710829,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾德生物(300685.SZ)公告，公司截止2024年10月31日以集中竞价交易方式实施回购股份466.62万股，占公司目前总股本的1.17%，支付的总金额为8583.5万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0005HP3H50.USD","LU2460026573.USD","BK0239","BK0042","300685"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1747428153524,"stockEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.017},{"period":"3month","weight":-0.1105},{"period":"6month","weight":-0.1994},{"period":"1year","weight":0.0281},{"period":"ytd","weight":-0.114}],"compareEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0062},{"period":"6month","weight":0.011},{"period":"1year","weight":0.0785},{"period":"ytd","weight":0.0047}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"厦门艾德生物医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24012人(较上一季度增加22.73%)","perCapita":"16225股","listingDate":"2017-08-02","address":"福建省厦门市海沧区鼎山路39号","registeredCapital":"39306万元","survey":" 厦门艾德生物医药科技股份有限公司的主营业务是肿瘤基因检测试剂、软件及配套仪器，并提供检测服务及药物临床研究服务。公司的主要产品是检测试剂、检测服务、药物临床研究服务。","listedPrice":13.86},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.5","shortVersion":"4.33.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾德生物(300685)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾德生物(300685)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾德生物,300685,艾德生物股票,艾德生物股票老虎,艾德生物股票老虎国际,艾德生物行情,艾德生物股票行情,艾德生物股价,艾德生物股市,艾德生物股票价格,艾德生物股票交易,艾德生物股票购买,艾德生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾德生物(300685)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾德生物(300685)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}